{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:30:08Z","timestamp":1761921008267,"version":"build-2065373602"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.msard.2022.103712","type":"journal-article","created":{"date-parts":[[2022,2,26]],"date-time":"2022-02-26T03:05:08Z","timestamp":1645844708000},"page":"103712","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["A one year follow of patients with multiple sclerosis during COVID-19 pandemic: A cross-sectional study in Qom province, Iran"],"prefix":"10.1016","volume":"60","author":[{"given":"Sepideh","family":"Paybast","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seyed Amir","family":"Hejazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Payam","family":"Molavi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Amin","family":"Habibi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8598-0911","authenticated-orcid":false,"given":"Abdorreza","family":"Naser Moghadasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.msard.2022.103712_bib0021","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1177\/13524585211003476","article-title":"COVID-19 vaccination in patients with multiple sclerosis: what we have learnt by February 2021","volume":"27","author":"Achiron","year":"2021","journal-title":"Mult. Scler. J."},{"issue":"43","key":"10.1016\/j.msard.2022.103712_bib0022","doi-asserted-by":"crossref","first-page":"6347","DOI":"10.1016\/j.vaccine.2021.09.030","article-title":"Naser Moghadasi A. Adverse events reported by Iranian patients with multiple sclerosis after the first dose of Sinopharm BBIBP-CorV","volume":"39","author":"Ali Sahraian","year":"2021","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.msard.2022.103712_bib0018","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/cei.13495","article-title":"COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases","volume":"202","author":"Baker","year":"2020","journal-title":"Clin. Exp. Immunol."},{"issue":"4","key":"10.1016\/j.msard.2022.103712_bib0023","doi-asserted-by":"crossref","first-page":"e1001","DOI":"10.1212\/NXI.0000000000001001","article-title":"COVID-19 among patients with multiple sclerosis","volume":"8","author":"Barzegar","year":"2021","journal-title":"Neurol Neuroimmunol. Neuroinflammation"},{"key":"10.1016\/j.msard.2022.103712_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102947","article-title":"Can coronavirus disease 2019 (COVID-19) trigger exacerbation of multiple sclerosis? A retrospective study","volume":"52","author":"Barzegar","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"4","key":"10.1016\/j.msard.2022.103712_bib0013","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000761","article-title":"COVID-19 and MS disease-modifying therapies","volume":"7","author":"Berger","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflammation"},{"issue":"2","key":"10.1016\/j.msard.2022.103712_bib0016","doi-asserted-by":"crossref","first-page":"138","DOI":"10.4103\/aian.AIAN_997_20","article-title":"Consensus statement on neurorehabilitation during COVID-19 times: expert group on behalf of the Indian federation of neurorehabilitation (IFNR)","volume":"24","author":"Dhamija","year":"2021","journal-title":"Ann. Indian Acad. Neurol."},{"issue":"11","key":"10.1016\/j.msard.2022.103712_bib0025","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.1007\/s00415-020-09996-w","article-title":"First case of SARS-COV-2 sequencing in cerebrospinal fluid of a patient with suspected demyelinating disease","volume":"267","author":"Domingues","year":"2020","journal-title":"J. Neurol."},{"issue":"13","key":"10.1016\/j.msard.2022.103712_bib0001","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1056\/NEJMe2002387","article-title":"COVID-19 \u2013 Navigating the Uncharted","volume":"382","author":"Fauci","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2022.103712_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2021.577755","article-title":"Initial clinical manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine","volume":"361","author":"Fujimori","year":"2021","journal-title":"J. Neuroimmunol."},{"issue":"6","key":"10.1016\/j.msard.2022.103712_bib0002","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s10096-020-03874-z","article-title":"The epidemiology and clinical information about COVID-19","volume":"39","author":"Ge","year":"2020","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"issue":"11","key":"10.1016\/j.msard.2022.103712_bib0006","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s11910-017-0800-8","article-title":"Infections in patients receiving multiple sclerosis disease-modifying therapies","volume":"17","author":"Grebenciucova","year":"2017","journal-title":"Curr. Neurol. Neurosci. Rep."},{"issue":"11","key":"10.1016\/j.msard.2022.103712_bib0010","doi-asserted-by":"crossref","first-page":"13605","DOI":"10.1007\/s11356-020-11499-0","article-title":"Spatial and temporal analysis of the COVID-19 incidence pattern in Iran","volume":"28","author":"Hazbavi","year":"2021","journal-title":"Environ. Sci. Pollut. Res."},{"issue":"11","key":"10.1016\/j.msard.2022.103712_bib0003","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/s41582-021-00556-y","article-title":"Apparent changes in the epidemiology and severity of multiple sclerosis","volume":"17","author":"Koch-Henriksen","year":"2021","journal-title":"Nat. Rev. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2022.103712_bib0014","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nri3787","article-title":"Type I interferons in infectious disease","volume":"15","author":"McNab","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.msard.2022.103712_bib0030","doi-asserted-by":"crossref","unstructured":"Michelena G., Casas M., Eizaguirre M.B., Pita M.C., Cohen L., Alonso R., \u00bf Can COVID-19 exacerbate multiple sclerosis symptoms? A case series analysis. Mult. Scler. Relat. Disord. [Internet]. 2021 Nov;103368. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034821006350.","DOI":"10.1016\/j.msard.2021.103368"},{"issue":"1","key":"10.1016\/j.msard.2022.103712_bib0007","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3233\/NRE-2004-19107","article-title":"Disability in elderly people with multiple sclerosis: an analysis of baseline data from the Sonya slifka longitudinal multiple sclerosis study","volume":"19","author":"Minden","year":"2004","journal-title":"NeuroRehabilitation"},{"key":"10.1016\/j.msard.2022.103712_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.clineuro.2020.105921","article-title":"Neurological manifestations of COVID-19 and other coronavirus infections: a systematic review","volume":"194","author":"Montalvan","year":"2020","journal-title":"Clin. Neurol. Neurosurg."},{"key":"10.1016\/j.msard.2022.103712_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.ensci.2020.100299","article-title":"A first presentation of multiple sclerosis with concurrent COVID-19 infection","volume":"22","author":"Moore","year":"2021","journal-title":"eNeurologicalSci"},{"issue":"12","key":"10.1016\/j.msard.2022.103712_bib0005","doi-asserted-by":"crossref","first-page":"4067","DOI":"10.3390\/jcm9124067","article-title":"Experience in multiple sclerosis patients with COVID-19 and disease-modifying therapies: a review of 873 published cases","volume":"9","author":"M\u00f6hn","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.msard.2022.103712_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.clineuro.2021.106563","article-title":"Can pulse steroid therapy increase the risk of infection by COVID-19 in patients with multiple sclerosis?","volume":"203","author":"Naser Moghadasi","year":"2021","journal-title":"Clin. Neurol. Neurosurg."},{"key":"10.1016\/j.msard.2022.103712_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102377","article-title":"Multiple sclerosis following SARS-CoV-2 infection","volume":"45","author":"Palao","year":"2020","journal-title":"Mult. Scler Relat. Disord."},{"issue":"4","key":"10.1016\/j.msard.2022.103712_bib0009","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S1473-3099(20)30858-6","article-title":"SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study","volume":"21","author":"Poustchi","year":"2021","journal-title":"Lancet Infect. Dis."},{"issue":"3","key":"10.1016\/j.msard.2022.103712_bib0008","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1212\/CON.0000000000000739","article-title":"Management of multiple sclerosis relapses","volume":"25","author":"Repovic","year":"2019","journal-title":"Contin. Lifelong Learn Neurol."},{"key":"10.1016\/j.msard.2022.103712_bib0015","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ijid.2021.08.013","article-title":"Side effects and perceptions following Sinopharm COVID-19 vaccination","volume":"111","author":"Saeed","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.msard.2022.103712_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102139","article-title":"Rethinking high-risk groups in COVID-19","volume":"42","author":"Vishnevetsky","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"11","key":"10.1016\/j.msard.2022.103712_bib0004","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1177\/1352458516681198","article-title":"Infection-related health care utilization among people with and without multiple sclerosis","volume":"23","author":"Wijnands","year":"2017","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2022.103712_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103225","article-title":"MENACTRIMS practice guideline for COVID-19 vaccination in patients with multiple sclerosis","volume":"56","author":"Yamout","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"2","key":"10.1016\/j.msard.2022.103712_bib0012","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1016\/j.jinf.2020.04.021","article-title":"Risk factors of critical & mortal COVID-19 cases: a systematic literature review and meta-analysis","volume":"81","author":"Zheng","year":"2020","journal-title":"J. Infect."},{"issue":"10","key":"10.1016\/j.msard.2022.103712_bib0020","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1111\/ene.14578","article-title":"Immunology of COVID-19 and disease-modifying therapies: the good, the bad and the unknown","volume":"28","author":"Zrzavy","year":"2021","journal-title":"Eur. J. Neurol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822002279?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822002279?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:58:25Z","timestamp":1761901105000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034822002279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":30,"alternative-id":["S2211034822002279"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2022.103712","relation":{},"ISSN":["2211-0348"],"issn-type":[{"type":"print","value":"2211-0348"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A one year follow of patients with multiple sclerosis during COVID-19 pandemic: A cross-sectional study in Qom province, Iran","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2022.103712","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103712"}}